{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,5,10]],"date-time":"2026-05-10T23:08:16Z","timestamp":1778454496679,"version":"3.51.4"},"publisher-location":"New York, NY","reference-count":62,"publisher":"Springer US","isbn-type":[{"value":"9781071650363","type":"print"},{"value":"9781071650370","type":"electronic"}],"license":[{"start":{"date-parts":[[2026,1,1]],"date-time":"2026-01-01T00:00:00Z","timestamp":1767225600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.springernature.com\/gp\/researchers\/text-and-data-mining"},{"start":{"date-parts":[[2026,1,1]],"date-time":"2026-01-01T00:00:00Z","timestamp":1767225600000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/www.springernature.com\/gp\/researchers\/text-and-data-mining"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":[],"published-print":{"date-parts":[[2026]]},"DOI":"10.1007\/978-1-0716-5037-0_15","type":"book-chapter","created":{"date-parts":[[2026,5,10]],"date-time":"2026-05-10T22:10:38Z","timestamp":1778451038000},"page":"205-220","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":0,"title":["Overview of Quantitative Clinical Pharmacology for T-Cell Engaging Bispecific Antibodies"],"prefix":"10.1007","author":[{"given":"Rong","family":"Deng","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Chi-Chung","family":"Li","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"297","published-online":{"date-parts":[[2026,5,1]]},"reference":[{"key":"15_CR1","doi-asserted-by":"publisher","first-page":"38","DOI":"10.1186\/s40364-021-00294-9","volume":"9","author":"S Zhou","year":"2021","unstructured":"Zhou S, Liu M, Ren F et al (2021) The landscape of bispecific T cell engager in cancer treatment. Biomark Res 9:38. https:\/\/doi.org\/10.1186\/s40364-021-00294-9","journal-title":"Biomark Res"},{"issue":"5","key":"15_CR2","doi-asserted-by":"publisher","first-page":"552","DOI":"10.1097\/CCO.0000000000000869","volume":"34","author":"PA Baeuerle","year":"2022","unstructured":"Baeuerle PA, Wesche H (2022) T-cell-engaging antibodies for the treatment of solid tumors: challenges and opportunities. Curr Opin Oncol\u00a034(5):552\u2013558. https:\/\/doi.org\/10.1097\/CCO.0000000000000869","journal-title":"Curr Opin Oncol"},{"issue":"24","key":"15_CR3","doi-asserted-by":"publisher","first-page":"2220","DOI":"10.1056\/NEJMoa2206913","volume":"387","author":"MJ Dickinson","year":"2022","unstructured":"Dickinson MJ, Carlo-Stella C, Morschhauser F et al (2022) Glofitamab for relapsed or refractory diffuse large B-cell lymphoma. New England J\u00a0Med 387(24):2220\u20132231. https:\/\/doi.org\/10.1056\/NEJMoa2206913","journal-title":"New England J Med"},{"issue":"9","key":"15_CR4","doi-asserted-by":"publisher","first-page":"3583","DOI":"10.1016\/j.apsb.2023.05.023","volume":"13","author":"Y Sun","year":"2023","unstructured":"Sun Y, Yu X, Wang X et al (2023) Bispecific antibodies in cancer therapy: target selection and regulatory requirements. Acta Pharm Sin B 13(9):3583\u20133597. https:\/\/doi.org\/10.1016\/j.apsb.2023.06.006","journal-title":"Acta Pharm Sin B"},{"key":"15_CR5","doi-asserted-by":"publisher","first-page":"301","DOI":"10.1038\/s41573-024-00896-6","volume":"23","author":"C Klein","year":"2024","unstructured":"Klein C, Brinkmann U, Reichert JM et al (2024) The present and future of bispecific antibodies for cancer therapy. Nat Rev Drug Discov 23:301\u2013319. https:\/\/doi.org\/10.1038\/s41573-024-00896-6","journal-title":"Nat Rev Drug Discov"},{"key":"15_CR6","unstructured":"Center for Drug Evaluation and Research, FDA (2022) Multi-disciplinary review and evaluation BLA 125557: blinatumomab"},{"key":"15_CR7","unstructured":"Center for Drug Evaluation and Research, FDA (2021) Multi-disciplinary review and evaluation BLA 761228: Kimmtrak (tebentafusp)"},{"key":"15_CR8","unstructured":"Center for Drug Evaluation and Research, FDA (2021) Multi-disciplinary review and evaluation BLA 761291: teclistamab"},{"key":"15_CR9","unstructured":"Center for Drug Evaluation and Research, FDA (2022) Multi-disciplinary review and evaluation BLA 761263: Lunsumio (Mosunetuzumab)"},{"key":"15_CR10","unstructured":"Center for Drug Evaluation and Research, FDA (2022) Multi-disciplinary review and evaluation BLA 761342: Talquetamab-tgvs"},{"key":"15_CR11","unstructured":"Center for Drug Evaluation and Research, FDA (2022) Multi-disciplinary review and evaluation BLA 761324: epcoritamab"},{"key":"15_CR12","unstructured":"Center for Drug Evaluation and Research, FDA (2022) Multi-disciplinary review and evaluation BLA 761345: Elranatamab"},{"key":"15_CR13","unstructured":"Center for Drug Evaluation and Research, FDA (2022) Multi-disciplinary review and evaluation BLA 761309: Glofitamab-gxbm (Columvi)"},{"key":"15_CR14","doi-asserted-by":"publisher","unstructured":"Li CC, Bender B, Wilkins J et al (2024) A Novel Step-Up Dosage Regimen for Enhancing the Benefit-to-Risk Ratio of Mosunetuzumab in Relapsed or Refractory Follicular Lymphoma. Clin Pharmacol Ther https:\/\/doi.org\/10.1002\/cpt.3445","DOI":"10.1002\/cpt.3445"},{"issue":"1","key":"15_CR15","doi-asserted-by":"publisher","first-page":"75","DOI":"10.1111\/cts.12877","volume":"14","author":"PN Morcos","year":"2021","unstructured":"Morcos PN, Li J, Hosseini I, Li CC (2021) Quantitative clinical pharmacology of T-cell engaging bispecifics: current perspectives and Opportunities. Clin Transl Sci 14(1):75\u201385. https:\/\/doi.org\/10.1111\/cts.12877","journal-title":"Clin Transl Sci"},{"issue":"4","key":"15_CR16","doi-asserted-by":"publisher","first-page":"776","DOI":"10.1158\/1535-7163.MCT-17-0657","volume":"17","author":"D Mandikian","year":"2018","unstructured":"Mandikian D, Takahashi N, Lo AA et al (2018) Relative target affinities of T-cell-dependent bispecific antibodies determine biodistribution in a solid tumor mouse model. Mol Cancer Ther 17(4):776\u2013785. https:\/\/doi.org\/10.1158\/1535-7163.MCT-17-0657","journal-title":"Mol Cancer Ther"},{"issue":"6","key":"15_CR17","doi-asserted-by":"publisher","first-page":"e13825","DOI":"10.1111\/cts.13825","volume":"17","author":"B Bender","year":"2024","unstructured":"Bender B, Li CC, Marchand M et al (2024) Population pharmacokinetics and CD20 binding dynamics for mosunetuzumab in relapsed\/refractory B-cell non-Hodgkin lymphoma. Clin Transl Sci 17(6):e13825. https:\/\/doi.org\/10.1111\/cts.13825","journal-title":"Clin Transl Sci"},{"key":"15_CR18","doi-asserted-by":"publisher","first-page":"56","DOI":"10.1186\/s40425-018-0343-9","volume":"6","author":"A Shimabukuro-Vornhagen","year":"2018","unstructured":"Shimabukuro-Vornhagen A, G\u00f6del P, Subklewe M et al (2018) Cytokine release syndrome. J\u00a0Immunotherapy Cancer 6:56","journal-title":"J Immunotherapy Cancer"},{"key":"15_CR19","doi-asserted-by":"publisher","first-page":"625","DOI":"10.1016\/j.bbmt.2018.12.758","volume":"25","author":"DW Lee","year":"2019","unstructured":"Lee DW, Santomasso BD, Locke FL et al (2019) ASTCT consensus grading for cytokine release syndrome and neurologic toxicity associated with immune effector cells. Biol Blood Marrow Transplant 25:625\u2013638","journal-title":"Biol Blood Marrow Transplant"},{"key":"15_CR20","unstructured":"FDA Guidance: bispecific antibody development programs, guidance for industry, May 2021, https:\/\/www.fda.gov\/media\/123313\/download"},{"issue":"10","key":"15_CR21","doi-asserted-by":"publisher","first-page":"5350","DOI":"10.3390\/ijms22105350","volume":"22","author":"AC Register","year":"2021","unstructured":"Register AC, Tarighat SS, Lee HY (2021) Bioassay development for bispecific antibodies-challenges and opportunities. Int J Mol Sci 22(10):5350. https:\/\/doi.org\/10.3390\/ijms22105350","journal-title":"Int J Mol Sci"},{"key":"15_CR22","doi-asserted-by":"publisher","first-page":"126","DOI":"10.1007\/s40495-017-0090-5","volume":"3","author":"Y Chen","year":"2017","unstructured":"Chen Y, Xu Y (2017) Pharmacokinetics of bispecific antibody. Curr Pharmacol Rep 3:126\u2013137. https:\/\/doi.org\/10.1007\/s40495-017-0090-5","journal-title":"Curr Pharmacol Rep"},{"issue":"2","key":"15_CR23","doi-asserted-by":"publisher","first-page":"182","DOI":"10.1080\/19420862.2016.1268307","volume":"9","author":"U Brinkmann","year":"2017","unstructured":"Brinkmann U, Kontermann RE (2017) The making of bispecific antibodies. MAbs 9(2):182\u2013212. https:\/\/doi.org\/10.1080\/19420862.2016.1268307","journal-title":"MAbs"},{"key":"15_CR24","doi-asserted-by":"publisher","first-page":"e13676","DOI":"10.1111\/cts.13676","volume":"17","author":"JR Proctor","year":"2024","unstructured":"Proctor JR, Wong H (2024) Time-dependent clearance can confound exposure-response analysis of therapeutic antibodies: A comprehensive review of the current literature. Clin Transl Sci 17:e13676. https:\/\/doi.org\/10.1111\/cts.13676","journal-title":"Clin Transl Sci"},{"key":"15_CR25","doi-asserted-by":"publisher","unstructured":"Radtke KK, Bender BC, Li Z et al (2024) Clinical pharmacology of cytokine release syndrome with T-cell engaging bispecific antibodies: current insights and drug development strategies. Clin Cancer Res https:\/\/doi.org\/10.1158\/1078-0432.CCR-24-2247","DOI":"10.1158\/1078-0432.CCR-24-2247"},{"key":"15_CR26","doi-asserted-by":"publisher","first-page":"7652","DOI":"10.3390\/ijms22147652","volume":"22","author":"M Cosenza","year":"2021","unstructured":"Cosenza M, Sacchi S, Pozzi S (2021) Cytokine release syndrome associated with T-cell-based therapies for hematological malignancies: pathophysiology, clinical presentation, and treatment. Int J Mol Sci 22:7652. https:\/\/doi.org\/10.3390\/ijms22147652","journal-title":"Int J Mol Sci"},{"key":"15_CR27","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1038\/s41540-020-00145-7","volume":"6","author":"I Hosseini","year":"2020","unstructured":"Hosseini I, Gadkar K, Stefanich E et al (2020) Mitigating the risk of cytokine release syndrome in a phase I trial of CD20\/CD3 bispecific antibody mosunetuzumab in NHL: impact of translational system modeling. NPJ Syst Biol Appl 6:1\u201311","journal-title":"NPJ Syst Biol Appl"},{"issue":"16","key":"15_CR28","doi-asserted-by":"publisher","first-page":"1565","DOI":"10.1182\/blood.2023022432","volume":"143","author":"J Crombie","year":"2024","unstructured":"Crombie J, Graff T, Falchi L et al (2024) Consensus recommendations on the management of toxicity associated with CD3\u00d7CD20 bispecific antibody therapy. Blood 143(16):1565\u20131575","journal-title":"Blood"},{"issue":"508","key":"15_CR29","doi-asserted-by":"publisher","first-page":"eaax8861","DOI":"10.1126\/scitranslmed.aax8861","volume":"11","author":"J Li","year":"2019","unstructured":"Li J, Piskol R, Ybarra R et al (2019) CD3 bispecific antibody-induced cytokine release is dispensable for cytotoxic T cell activity. Sci Transl Med 11(508):eaax8861. https:\/\/doi.org\/10.1126\/scitranslmed.aax8861","journal-title":"Sci Transl Med"},{"issue":"1","key":"15_CR30","doi-asserted-by":"publisher","first-page":"2181016","DOI":"10.1080\/19420862.2023.2181016","volume":"15","author":"K Ball","year":"2023","unstructured":"Ball K, Dovedi SJ, Vajjah P, Phipps A (2023) Strategies for clinical dose optimization of T cell-engaging therapies in oncology. MAbs 15(1):2181016. https:\/\/doi.org\/10.1080\/19420862.2023.2181016","journal-title":"MAbs"},{"issue":"Suppl 1","key":"15_CR31","doi-asserted-by":"publisher","first-page":"3753","DOI":"10.1182\/blood-2022-157729","volume":"140","author":"EL Budde","year":"2022","unstructured":"Budde EL, Bartlett NL, Giri P et al (2022) Subcutaneous mosunetuzumab is active with a manageable safety profile in patients with relapsed\/refractory B-cell non-Hodgkin lymphomas: updated results from a phase I\/II study. Blood 140(Suppl 1):3753\u20133755. https:\/\/doi.org\/10.1182\/blood-2022-157729","journal-title":"Blood"},{"issue":"16_suppl","key":"15_CR32","doi-asserted-by":"publisher","first-page":"8007","DOI":"10.1200\/JCO.2022.40.16_suppl.8007","volume":"40","author":"AK Nooka","year":"2022","unstructured":"Nooka AK, Moreau P, Usmani SZ et al (2022) Teclistamab, a B-cell maturation antigen (BCMA) x CD3 bispecific antibody, in patients with relapsed\/refractory multiple myeloma (RRMM): updated efficacy and safety results from MajesTEC-1. J Clin Oncol 40(16_suppl):8007\u20138007. https:\/\/doi.org\/10.1200\/JCO.2022.40.16_suppl.8007","journal-title":"J Clin Oncol"},{"issue":"16_suppl","key":"15_CR33","doi-asserted-by":"publisher","first-page":"8015","DOI":"10.1200\/JCO.2022.40.16_suppl.8015","volume":"40","author":"MC Minnema","year":"2022","unstructured":"Minnema MC, Krishnan AY, Berdeja JG et al (2022) Efficacy and safety of talquetamab, a G protein-coupled receptor family C group 5 member D x CD3 bispecific antibody, in patients with relapsed\/refractory multiple myeloma (RRMM): updated results from MonumenTAL-1. J Clin Oncol 40(16_suppl):8015\u20138015. https:\/\/doi.org\/10.1200\/JCO.2022.40.16_suppl.8015","journal-title":"J Clin Oncol"},{"key":"15_CR34","doi-asserted-by":"publisher","first-page":"2798","DOI":"10.1158\/1538-7445.AM2023-2798","volume":"83","author":"T Li","year":"2023","unstructured":"Li T, Polhamus D, Thalhauser C et al (2023) Abstract 2798: simplifying selection and optimization of step-up dosing of subcutaneous Epcoritamab to mitigate CRS risk using repeated time-to-event modeling. Cancer Res 83:2798","journal-title":"Cancer Res"},{"issue":"5","key":"15_CR35","doi-asserted-by":"publisher","first-page":"1108","DOI":"10.1002\/cpt.2729.","volume":"112","author":"T Li","year":"2022","unstructured":"Li T, Hiemstra IH, Chiu C et al (2022) Semimechanistic physiologically-based pharmacokinetic\/pharmacodynamic model informing epcoritamab dose selection for patients with B-cell lymphomas. Clin Pharmacol Ther 112(5):1108\u20131119. https:\/\/doi.org\/10.1002\/cpt.2729","journal-title":"Clin Pharmacol Ther"},{"key":"15_CR36","unstructured":"Genentech, Inc. (2025) Actemra (tocilizumab) injection, for intravenous or subcutaneous use [Prescribing information]. U.S. Food and Drug Administration. https:\/\/www.gene.com\/download\/pdf\/actemra_prescribing.pdf"},{"key":"15_CR37","doi-asserted-by":"publisher","first-page":"3959","DOI":"10.1182\/blood-2008-05-155846","volume":"112","author":"N Nishimoto","year":"2008","unstructured":"Nishimoto N, Terao K, Mima T et al (2008) Mechanisms and pathologic significances in increase in serum interleukin-6 (IL-6) and soluble IL-6 receptor after administration of an anti\u2013IL-6 receptor antibody, tocilizumab, in patients with rheumatoid arthritis and Castleman disease. Blood 112:3959\u20133964","journal-title":"Blood"},{"key":"15_CR38","doi-asserted-by":"crossref","unstructured":"Bender B, Schoemaker R, Li Z, Li F, Vadhavkar S, Lu J, Susilo M, Turner D, Li CC, Chanu P (2024) A multi-stage modeling approach towards predicting cytokine release syndrome (CRS) in patients receiving Mosunetuzumab. ACoP Conference 2024, Poster T-011","DOI":"10.70534\/ZNTH8316"},{"key":"15_CR39","doi-asserted-by":"publisher","first-page":"4670","DOI":"10.1182\/blood-2023-180208","volume":"142","author":"J Zhou","year":"2023","unstructured":"Zhou J, Vishwamitra D, Guo Y et al (2023) Model-based exploration of the impact of prophylactic tocilizumab on IL-6 dynamics in multiple myeloma patients receiving teclistamab treatment. Blood 142:4670","journal-title":"Blood"},{"issue":"8","key":"15_CR40","doi-asserted-by":"publisher","first-page":"1669","DOI":"10.1007\/s11095-022-03288-w","volume":"39","author":"R Madabushi","year":"2022","unstructured":"Madabushi R, Seo P, Zhao L, Tegenge M, Zhu H (2022) Review: role of model-informed drug development approaches in the lifecycle of drug development and regulatory decision-making. Pharm Res 39(8):1669\u20131680. https:\/\/doi.org\/10.1007\/s11095-022-03288-w","journal-title":"Pharm Res"},{"issue":"2","key":"15_CR41","doi-asserted-by":"publisher","first-page":"315","DOI":"10.1002\/cpt.3308","volume":"116","author":"K Lim","year":"2024","unstructured":"Lim K, Zhu XS, Zhou D, Ren S, Phipps A (2024) Clinical pharmacology strategies for bispecific antibody development: learnings from FDA-approved bispecific antibodies in oncology. Clin Pharmacol Ther 116(2):315\u2013327. https:\/\/doi.org\/10.1002\/cpt.3308","journal-title":"Clin Pharmacol Ther"},{"issue":"5","key":"15_CR42","doi-asserted-by":"publisher","first-page":"435","DOI":"10.1007\/BF01059667","volume":"1","author":"RL Dedrick","year":"1973","unstructured":"Dedrick RL (1973) Animal scale-up. J\u00a0Pharmacokinet Biopharm 1(5):435\u2013461","journal-title":"J Pharmacokinet Biopharm"},{"key":"15_CR43","unstructured":"Mahmood I (2005) Prediction of concentration-time profiles in humans. Pine House Publisher, Rockville"},{"issue":"10","key":"15_CR44","doi-asserted-by":"publisher","first-page":"3850","DOI":"10.1002\/jps.21682","volume":"98","author":"I Mahmood","year":"2009","unstructured":"Mahmood I (2009) Pharmacokinetic allometric scaling of antibodies: application to the first-in-human dose estimation. J\u00a0Pharm Sci 98(10):3850\u20133861. https:\/\/doi.org\/10.1002\/jps.21682","journal-title":"J Pharm Sci"},{"issue":"9","key":"15_CR45","doi-asserted-by":"publisher","first-page":"1297","DOI":"10.1124\/dmd.105.004143","volume":"33","author":"H Tang","year":"2005","unstructured":"Tang H, Mayersohn M (2005) A novel model for prediction of human drug clearance by allometric scaling. Drug Metab Dispos 33(9):1297\u20131303. https:\/\/doi.org\/10.1124\/dmd.105.004143","journal-title":"Drug Metab Dispos"},{"issue":"3","key":"15_CR46","doi-asserted-by":"publisher","first-page":"147","DOI":"10.1111\/cts.12459","volume":"10","author":"A Trivedi","year":"2017","unstructured":"Trivedi A, Stienen S, Zhu M et al (2017) Clinical pharmacology and translational aspects of bispecific antibodies. Clin Transl Sci 10(3):147\u2013162. https:\/\/doi.org\/10.1111\/cts.12459","journal-title":"Clin Transl Sci"},{"issue":"3","key":"15_CR47","doi-asserted-by":"publisher","first-page":"177","DOI":"10.1002\/psp4.12369","volume":"8","author":"J Schropp","year":"2019","unstructured":"Schropp J, Khot A, Shah DK, Koch G (2019) Target-mediated drug disposition model for bispecific antibodies: properties, approximation, and optimal dosing strategy. CPT Pharmacometrics Syst Pharmacol 8(3):177\u2013187. https:\/\/doi.org\/10.1002\/psp4.12369","journal-title":"CPT Pharmacometrics Syst Pharmacol"},{"issue":"6","key":"15_CR48","doi-asserted-by":"publisher","first-page":"1395","DOI":"10.1002\/cpt.2009","volume":"109","author":"MW Leach","year":"2021","unstructured":"Leach MW, Clarke DO, Dudal S, Han C, Li C, Yang Z, Brennan FR, Bailey WJ, Chen Y, Deslandes A, Loberg LI, Mayawala K, Rogge MC, Todd M, Chemuturi NV (2021) Strategies and recommendations for using a data-driven and risk-based approach in the selection of first-in-human starting dose: an International Consortium for Innovation and Quality in Pharmaceutical Development (IQ) assessment. Clin Pharmacol Ther 109(6):1395\u20131415. https:\/\/doi.org\/10.1002\/cpt.2009","journal-title":"Clin Pharmacol Ther"},{"key":"15_CR49","doi-asserted-by":"publisher","unstructured":"Nagaraja Shastri P, Shah N, Lechmann M, Mody H, Retter MW, Zhu M, Li T, Wang J, Shaik N, Zheng X, Ovacik M, Hua F, Jawa V, Boetsch C, Cao Y, Burke J, Datta K, Gadkar K, Upreti V, Betts A (2024) Industry perspective on first-in-human and clinical pharmacology strategies to support clinical development of T-cell engaging bispecific antibodies for cancer therapy. Clin Pharmacol Ther 2024. https:\/\/doi.org\/10.1002\/cpt.3439","DOI":"10.1002\/cpt.3439"},{"key":"15_CR50","doi-asserted-by":"publisher","first-page":"144","DOI":"10.1016\/j.yrtph.2017.09.001","volume":"90","author":"H Saber","year":"2017","unstructured":"Saber H, Del Valle P, Ricks TK, Leighton JK (2017) An FDA oncology analysis of CD3 bispecific constructs and first-in-human dose selection. Regul Toxicol Pharmacol 90:144\u2013152. https:\/\/doi.org\/10.1016\/j.yrtph.2017.09.001","journal-title":"Regul Toxicol Pharmacol"},{"key":"15_CR51","doi-asserted-by":"publisher","unstructured":"Liao X, Qi T, Zhou J, Liu C, Cao Y (2024) Optimizing clinical translation of bispecific T-cell engagers through context unification with a quantitative systems pharmacology model. Clin Pharmacol Ther https:\/\/doi.org\/10.1002\/cpt.3302","DOI":"10.1002\/cpt.3302"},{"key":"15_CR52","doi-asserted-by":"publisher","first-page":"e83659","DOI":"10.7554\/eLife.83659","volume":"12","author":"C Liu","year":"2023","unstructured":"Liu C, Zhou J, Kudlacek S et al (2023) Population dynamics of immunological synapse formation induced by bispecific T cell engagers predict clinical pharmacodynamics and treatment resistance. Elife 12:e83659. https:\/\/doi.org\/10.7554\/eLife.83659","journal-title":"Elife"},{"key":"15_CR53","doi-asserted-by":"publisher","first-page":"1134","DOI":"10.1111\/cts.13501","volume":"16","author":"ME Susilo","year":"2023","unstructured":"Susilo ME, Li CC, Gadkar K et al (2023) Systems-based digital twins to help characterize clinical dose\u2013response and propose predictive biomarkers in a phase I study of bispecific antibody, mosunetuzumab, in NHL. Clin Transl Sci 16:1134\u20131148","journal-title":"Clin Transl Sci"},{"key":"15_CR54","doi-asserted-by":"publisher","first-page":"1543","DOI":"10.1002\/psp4.12864","volume":"11","author":"KF Chen","year":"2022","unstructured":"Chen KF, Jones HM (2022) PBPK perspective on alternative CYP3A4 inducers for rifampin. CPT Pharmacometrics Syst Pharmacol 11:1543\u20131546. https:\/\/doi.org\/10.1002\/psp4.12864","journal-title":"CPT Pharmacometrics Syst Pharmacol"},{"issue":"9","key":"15_CR55","doi-asserted-by":"publisher","first-page":"507","DOI":"10.1002\/psp4.12003","volume":"4","author":"Y Xu","year":"2015","unstructured":"Xu Y, Hijazi Y, Wolf A, Wu B, Sun YN, Zhu M (2015) Physiologically based pharmacokinetic model to assess the influence of blinatumomab-mediated cytokine elevations on cytochrome P450 enzyme activity. CPT Pharmacometrics Syst Pharmacol 4(9):507\u2013515. https:\/\/doi.org\/10.1002\/psp4.12003","journal-title":"CPT Pharmacometrics Syst Pharmacol"},{"issue":"2","key":"15_CR56","doi-asserted-by":"publisher","first-page":"234","DOI":"10.1002\/psp4.13073","volume":"13","author":"Y Chen","year":"2024","unstructured":"Chen Y, Ma F, Jones N, Deng R, Li C, Li CC (2024) Assessment of CYP3A-mediated drug interaction via cytokine (IL-6) elevation for mosunetuzumab using physiologically-based pharmacokinetic modeling. CPT Pharmacometrics Syst Pharmacol 13(2):234\u2013246. https:\/\/doi.org\/10.1002\/psp4.13073","journal-title":"CPT Pharmacometrics Syst Pharmacol"},{"key":"15_CR57","doi-asserted-by":"publisher","first-page":"112609","DOI":"10.1016\/j.intimp.2024.112609","volume":"138","author":"J Liu","year":"2024","unstructured":"Liu J, Zhu J (2024) Progresses of T-cell-engaging bispecific antibodies in treatment of solid tumors. Int Immunopharmacol 138:112609. https:\/\/doi.org\/10.1016\/j.intimp.2024.112609","journal-title":"Int Immunopharmacol"},{"issue":"2","key":"15_CR58","doi-asserted-by":"publisher","first-page":"465","DOI":"10.1016\/j.intimp.2014.07.024","volume":"22","author":"F Xiong","year":"2014","unstructured":"Xiong F, Janko M, Walker M, Makropoulos D, Weinstock D, Kam M, Hrebien L (2014) Analysis of cytokine release assay data using machine learning approaches. Int Immunopharmacol 22(2):465\u2013479. https:\/\/doi.org\/10.1016\/j.intimp.2014.07.024","journal-title":"Int Immunopharmacol"},{"key":"15_CR59","doi-asserted-by":"publisher","unstructured":"Mann J, Meshkin H, Zirkle J et al Mechanism-based organization of neural networks to emulate systems biology and pharmacology models. Sci Rep 14:12082. https:\/\/doi.org\/10.1038\/s41598-024-59378-9","DOI":"10.1038\/s41598-024-59378-9"},{"issue":"6","key":"15_CR60","doi-asserted-by":"publisher","first-page":"601","DOI":"10.1097\/CCO.0000000000000983","volume":"35","author":"NWCJ van de Donk","year":"2023","unstructured":"van de Donk NWCJ, O'Neill C, de Ruijter MEM, Verkleij CPM, Zweegman S (2023) T-cell redirecting bispecific and trispecific antibodies in multiple myeloma beyond BCMA. Curr Opin Oncol 35(6):601\u2013611. https:\/\/doi.org\/10.1097\/CCO.0000000000000983","journal-title":"Curr Opin Oncol"},{"issue":"525","key":"15_CR61","doi-asserted-by":"publisher","first-page":"eaaw7888","DOI":"10.1126\/scitranslmed.aaw7888","volume":"12","author":"D Skokos","year":"2020","unstructured":"Skokos D, Waite JC, Haber L, Yancopoulos GD et al (2020) A class of costimulatory CD28-bispecific antibodies that enhance the antitumor activity of CD3-bispecific antibodies. Sci Transl Med 12(525):eaaw7888. https:\/\/doi.org\/10.1126\/scitranslmed.aaw7888","journal-title":"Sci Transl Med"},{"issue":"1","key":"15_CR62","doi-asserted-by":"publisher","first-page":"132","DOI":"10.3390\/pharmaceutics15010132","volume":"15","author":"C Carrasco-Padilla","year":"2022","unstructured":"Carrasco-Padilla C, Hernaiz-Esteban A, \u00c1lvarez-Vallina L, Aguilar-Sope\u00f1a O, Roda-Navarro P (2022) Bispecific antibody format and the organization of immunological synapses in T cell-redirecting strategies for cancer immunotherapy. Pharmaceutics 15(1):132. https:\/\/doi.org\/10.3390\/pharmaceutics15010132","journal-title":"Pharmaceutics"}],"container-title":["Methods in Molecular Biology","Bispecific Antibodies"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/978-1-0716-5037-0_15","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,5,10]],"date-time":"2026-05-10T22:10:41Z","timestamp":1778451041000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1007\/978-1-0716-5037-0_15"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026]]},"ISBN":["9781071650363","9781071650370"],"references-count":62,"URL":"https:\/\/doi.org\/10.1007\/978-1-0716-5037-0_15","relation":{},"ISSN":["1064-3745","1940-6029"],"issn-type":[{"value":"1064-3745","type":"print"},{"value":"1940-6029","type":"electronic"}],"subject":[],"published":{"date-parts":[[2026]]},"assertion":[{"value":"1 May 2026","order":1,"name":"first_online","label":"First Online","group":{"name":"ChapterHistory","label":"Chapter History"}}]}}